Rhythm Pharmaceuticals, Inc. (RYTM) Cash Flow Statement

The reported OCF/NI ratio above 1.0 in Q2 2026 suggests that operating cash burn is actually less severe than net income implies, but this is largely due to non-cash stock-based compensation. Excluding SBC, cash burn would be significantly higher, indicating that the quality of earnings is poor and the company is still consuming cash at an unsustainable rate.

The widening FCF deficit despite 45.8% revenue growth indicates that operating expenses are scaling faster than gross profit, and the company has not yet achieved the operating leverage needed to narrow cash burn. With TTM FCF of approximately -$190M against a cash balance of $54.3M, the trajectory suggests an imminent need for external financing.

The near-zero capex underscores a business model that relies on outsourced manufacturing and a commercial infrastructure that is largely variable. This means that the primary cash drain is operating expenses, particularly SG&A and R&D, rather than fixed asset investment, which could allow for faster margin improvement if revenue growth continues.

The volatility in working capital suggests that revenue recognition and cash collection are not perfectly aligned, possibly due to gross-to-net adjustments and international reimbursement timing. While the swings are not large relative to total cash burn, they add unpredictability to quarterly cash flow and warrant monitoring for any deterioration in collection efficiency.

The absence of capital returns is typical for a pre-profit biotech, but it highlights that the company is entirely dependent on external financing to sustain its burn. With a debt/equity ratio of 0.01, the company has not leveraged its balance sheet, but the low cash balance suggests that equity dilution is the likely path to funding future operations.

The divergence between net income and operating cash flow is primarily due to stock-based compensation and depreciation, which are non-cash but represent real economic costs to shareholders. This suggests that the company's cash runway is longer than net income alone would imply, but the dilution from SBC is a hidden cost that investors should factor into their valuation.